Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Piper Sandler analyst David Amsellem reiterates Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $118 to...
Novo's upcoming Alzheimer's trial results will test whether Rybelsus can slow cognitive decline and reshape treatment e...
Biogen Inc. (NASDAQ:BIIB) today announced upcoming scientific presentations at the 18th Clinical Trials on Alzheimer's Dis...
– Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden...
If adopted by the European Commission, the high dose regimen will be an additional dosing option to the already approved 12 mg ...
Stifel analyst Paul Matteis upgrades Biogen (NASDAQ:BIIB) from Hold to Buy and raises the price target from $144 to $202.
Bernstein analyst William Pickering maintains Biogen (NASDAQ:BIIB) with a Market Perform and raises the price target from $1...
Oral presentation to share first-of-its-kind longitudinal gene expression data in IgA nephropathy, unveiling novel insights int...
